Given that the 21-gene RS is a promising tool that can guide a chemotherapy decision in early-stage breast cancer patients with hormone receptor-positive and HER2-negative tumor, a shared-decision making with patients, using the multigene assay result and discussions about known risks and benefits of chemotherapy should be warranted in the era of personalized medicine. Here, ERBB2 is linked to breast carcinoma.